(Rac)-Apremilast

(Rac)-Apremilast

• CAS Number: 253168-86-4
• UNSPSC Description: (Rac)-Apremilast ((Rac)-CC-10004) is the racemic mixture of Apremilast. (Rac)-Apremilast has anti-inflammatory properties and can be used for research on inflammatory diseases, such as psoriasis[1][2].
• Target Antigen: Others
• Type: Reference compound
• Related Pathways: Others
• Field of Research: Inflammation/Immunology
• Assay Protocol: https://www.medchemexpress.com/rac-apremilast.html
• Purity: 99.53
• Smiles: CC(NC1=CC=CC(C(N2C(C3=CC=C(OC)C(OCC)=C3)CS(=O)(C)=O)=O)=C1C2=O)=O
• Molecular Weight: 460.50
• References & Citations: [1]Armstrong AW, et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial. J Am Acad Dermatol. 2023 Jan;88(1):29-39. |[2]Man H W, et al. Discovery of (S)-N-{2-[1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1, 3-dioxo-2, 3-dihydro-1 H-isoindol-4-yl} acetamide (apremilast), a potent and orally active phosphodiesterase 4 and tumor necrosis factor-α inhibitor[J]. Journal of medicinal chemistry, 2009, 52(6): 1522-1524.
• Shipping Conditions: Room Temperature
• Storage Conditions: -20°C, 3 years; 4°C, 2 years (Powder)
• Clinical Information: No Development Reported